Patent application number | Description | Published |
20120119686 | Method for controlling a motor - A method for controlling a motor by an inverter and by a vectorial technique, comprising the following steps: determining the value of a quadrature current Iq necessary for said motor to generate the desired torque; calculating the value of a direct current to be supplied to the motor by an equation as a function of the phase of the current vector on which the torque constant of the motor depends; calculating the power current of said motor from the direct current and the quadrature current; supplying the power current to the motor through the inverter. | 05-17-2012 |
20140022727 | Cooling device for electronic components and control apparatus comprising the cooling device - A cooling device for electronic components includes a substantially prismatic body made of a thermally conductive material, which has a pair of substantially planar main outer surfaces and encloses therein at least one circuit for the flow of a cooling fluid. Both main outer surfaces are designed to allow removable attachment of an electronic component to be cooled. A control apparatus incorporating the device. | 01-23-2014 |
20140035402 | Electric Generator - An electric energy generator includes a driving shaft designed to be coupled to an external energy source having a predetermined torque, a synchronous reluctance rotating electric machine having a stator and a transverse-laminated rotor, and a driven shaft operatively coupled to the drive shaft for generating electric energy with a predetermined torque ripple amplitude, an electric connection for injecting the electric energy so generated into the net, a control system designed to adjusting electrical and dynamic parameters of the electric machine. The stator has an even number of longitudinal grooves for each pair of poles and the rotor has a plurality of adjacent slots defining an even number of magnetically equivalent slots. The number of grooves is different from the number of equivalent slots multiplied by an integer, the difference between the number of grooves and the number of equivalent slots being different form zero, +2 and −2. | 02-06-2014 |
20140239858 | Movement control system for a drilling plant - A movement control system for a drilling plant includes a first hydraulic circuit with an inlet duct and an outlet duct for a working fluid, a pumping device of reversible type promoting the circulation of the fluid, first electric machine mechanically coupled to the pumping device to promote circulation of the fluid in the first hydraulic circuit, wherein the first electric machine is connected to an electric circuit connectable to the net or to an electric accumulator. The first electric machine selectively operates as an electric motor to promote circulation of the fluid in a first sense and to drive the actuating means during the rise of the drilling head, and as an electric generator upon fluid flow in a second, opposite sense during the lowering of the drilling head to inject in the network or in the accumulator the electric power generated by the first machine. | 08-28-2014 |
20140291988 | Electric Generator - An electric generator (1) for the conversion of energy from a renewable energy source, such as wind energy, into electrical energy to be inserted into a local or remote network (R), which comprises a rotary electric machine (2) provided with means (3) for drawing energy from the renewable source and for converting into electrical energy, first control means (4) for regulating the functioning parameters of the machine (2), second control means (5) for regulating the parameters of the electrical energy generated by the machine (2), and connection means (6) for electrically connecting the second control means (5) to the network (R), wherein the machine (2) is positioned in a space (V) placed at a predetermined distance (h) with respect to a base (B) that is fixed or anchorable with respect to the ground (T). The first control means (4) are housed in a first case (7) placed inside the space (V), the second control means (5) are housed in a second case (8) that is different and spatially offset with respect of the first, and the second control means (5) are electrically connected to the first control means (4), to facilitate the mounting and the maintenance of the generator. | 10-02-2014 |
Patent application number | Description | Published |
20090053218 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. | 02-26-2009 |
20090074771 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
20090076251 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
20110097323 | Her2/neu-Specific Antibodies and Methods of Using Same - This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 04-28-2011 |
20120034221 | T-Cell Receptor Antibodies And Methods of Use Thereof - The present invention is directed to the production and use of monoclonal antibodies, or antigen binding fragments thereof, that specifically bind the T cell antigen receptor (TCR) and their use for immunomodulation. In preferred embodiments, the antibody or antigen binding fragment of the invention specifically binds the constant region of the α chain of the TCR, or otherwise specifically binds the α chain regardless of TCR clonal origin (i.e., is pan specific for TCR). The antibodies of the invention may be used, for example, in immunosuppressive therapies for transplant maintenance and the treatment of autoimmune diseases, and/or as targeting molecules for use in the treatment of T-cell malignancies. | 02-09-2012 |
20140328836 | HER2/neu-Specific Antibodies and Methods of Using Same - This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 11-06-2014 |
20150175697 | Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life - The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules. | 06-25-2015 |
20160046714 | Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity - The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies. | 02-18-2016 |
Patent application number | Description | Published |
20100269976 | PROCESS AND PLANT FOR BUILDING TYRES FOR VEHICLE WHEELS - A process for building tyres for vehicle wheels wherein each tyre includes a carcass structure and a crown structure, the crown structure including a belt structure including a first radially inner belt layer and at least one second belt layer radially external to the first belt layer, the process including the steps of: a) placing an annular assembly including a first radially inner belt layer and at least one second radially outer belt layer on at least one auxiliary turning up drum; b) defining at least one pair of folding lines in axially opposite positions of the annular assembly by respective abutment devices radially external to the auxiliary turning up drum; c) adjusting the axial position of the folding lines relative to a centre line plane of the auxiliary turning up drum; and d) turning up, at the folding lines, at least a part of end portions of the first belt layer axially protruding relative to the at least one second belt layer on the at least one second belt layer of the annular assembly. | 10-28-2010 |
20100276067 | PROCESS AND PLANT FOR BUILDING TYRES FOR VEHICLE WHEELS - A process for building tyres for vehicle wheels includes the steps of: i) building a carcass structure of a green tyre in at least one carcass structure building line, the carcass structure including at least one carcass ply and a pair of annular anchoring structures; ii) building a crown structure of a green tyre in at least one crown structure building line, the crown structure including a belt structure and a tread band; wherein step ii) of building the crown structure includes at least one step iii) of building the belt structure which in turn includes the steps of: a) building on at least one first building drum, an annular assembly including a first radially inner belt layer and at least a second belt layer radially external to the first belt layer; b) transferring the annular assembly on at least one auxiliary drum; c) turning up axially opposite end portions of the fast radially inner belt layer so as to obtain at least a partial overlapping of the end portions of the first belt layer on the at least one second radially outer belt layer; and d) transferring said annular assembly from the at least one auxiliary drum on at least one second building drum. | 11-04-2010 |
20100307662 | PROCESS AND PLANT FOR PRODUCING TYRES FOR VEHICLE WHEELS - A plant and a process for producing tyres for vehicle wheels, includes the steps of: a) building a carcass structure of a green tyre on a first forming drum in at least one carcass structure building line, the carcass structure including at least one carcass ply and a pair of annular anchoring structures; b) building a crown structure of a green tyre on at least one second forming drum in at least one crown structure building line, the crown structure including at least one belt structure and a tread band; c) toroidally shaping the carcass structure assembling it to the crown structure in at least one assembling and shaping work station for the tyre being processed, the assembling and shaping work station being synchronised with the carcass structure building line and with the crown structure building line; wherein each carcass structure is associated with the respective first forming drum whereon it is built up to the end of step c) of shaping and assembling the tyre being processed; and d) moulding and vulcanizing the green shaped tyre in at least one tyre moulding and vulcanizing line separate from said assembling and shaping work station. | 12-09-2010 |
20110247741 | PROCESS FOR MANUFACTURING A TYRE, AND TYRE OBTAINED THEREFROM - During building of a carcass structure, a liner is applied around an outer surface of a primary drum by: circumferentially winding at least one pair of sheets of elastomeric material around an outer surface of the primary drum, which sheets are axially spaced apart from each other so as to form respective axially external portions of the liner; laying at least one continuous elongated element of elastomeric material in the form of a plurality of mutually approached coils around the outer surface of the primary drum in order to form a central portion of the liner having axially external edges that are each associated with an axially internal edge of one of said axially external portions of the liner. | 10-13-2011 |